HupA, Huperzina A, Huperzine, Huperzine-A, Selagine, Sélagine.<br/><br/>
Overview InformationHuperzine A is a chemical extracted from the Chinese club moss plant. Although the makers of huperzine A start with the plant, the final product is isolated and highly purified in the lab. As a result, some people regard huperzine A as a drug and argue that it shouldn't be considered a dietary supplement.
Be careful not to confuse huperzine A, which is also called selagine, with similar sounding medications such as selegiline (Eldepryl). Also be careful not to confuse one of the brand names for huperzine A (Cerebra) with the brand names for unrelated prescription drugs such as celecoxib (Celebrex), citalopram (Celexa), and fosphenytoin (Cerebyx).
Huperzine A is commonly used by mouth to improve memory and mental function in people with Alzheimer's disease, other types of dementia, age-related memory loss, and other conditions.
Products that combine huperzine A with certain drugs used for treating Alzheimer's disease are being studied. These "hybrid" products are of interest because they may be effective at lower doses and, therefore, cause fewer side effects. One hybrid, called huprine X, combines huperzine A with the drug donepezil. Another hybrid being studied contains huperzine A and the drug tacrine.
How does it work?Huperzine A is thought to be beneficial for problems with memory, loss of mental abilities (dementia), and the muscular disorder myasthenia gravis because it causes an increase in the levels of acetylcholine. Acetylcholine is one of the chemicals that our nerves use to communicate in the brain, muscles, and other areas. However, huperzine A might also have other effects. It seems to prevent death of some cells and it might prevent changes in cells by acting as an antioxidant.
Uses & Effectiveness
Possibly Effective for
- Dementia. Taking huperzine A by mouth for up to 36 weeks may improve memory, mental function, and behavior in people with conditions such as Alzheimer's disease or dementia. The effects of huperzine A in people with dementia when used for longer than 36 weeks is unknown.
- Memory. Some research shows that taking huperzine A by mouth for 4 weeks improves the memory older children and teenagers who complain of memory problems.
Insufficient Evidence for
- Cocaine addiction. Early research in a small number of people with cocaine addiction shows that taking huperzine by mouth might reduce some side effects of cocaine.
- Mental impairment. Early research shows that taking huperzine A by mouth for 12 weeks might improve memory in adults with mild mental impairment.
- Depression. Early research shows that taking huperzine A by mouth does not reduce feelings of sadness in people with depression. However, it might help memory.
- A muscular disorder called myasthenia gravis. Early research shows that giving huperzine A as an injection into the muscle for 10 days may prevent muscle weakness in patients with myasthenia gravis and may have equal or longer lasting effects compared to the drug neostigmine.
- Schizophrenia. Several studies show that taking huperzine A by mouth in addition to medications used for schizophrenia improves memory and some symptoms of schizophrenia. But these studies have been small and short-term. Larger, long-term studies are needed.
- Age-related memory loss.
- Increasing alertness and energy.
- Protection from agents poisonous to nerves.
- Other conditions.
Side Effects & SafetyHuperzine A is POSSIBLY SAFE in adults when taken by mouth for a short period of time (less than 6 months). It can cause some side effects including nausea, diarrhea, vomiting, dry mouth, constipation, sweating, blurred vision, slurred speech, fainting, restlessness, loss of appetite, contraction and twitching of muscle fibers, cramping, increased saliva and urine, inability to control urination, high blood pressure, swelling, dizziness, inability to sleep, and slowed heart rate.
Special Precautions & Warnings:Children: Huperzine A is POSSIBLY SAFE in children when taken by mouth for a short period of time (less than one month). Pregnancy and breast-feeding: There is not enough reliable information about the safety of taking huperzine A if you are pregnant or breast-feeding. Stay on the safe side and avoid use.
Slow heart rate or other heart diseases: Huperzine A can slow the heart rate. This might be a problem for people who already have a slow heart rate or other heart conditions involving the heart rate. If you have heart disease, use huperzine A cautiously.
Epilepsy: Since huperzine A seems to affect brain chemicals, there is concern that it might make epilepsy worse. If you have a seizure disorder such as epilepsy, use huperzine A cautiously.
Gastrointestinal (GI) tract blockage: There is a concern that using huperzine A might make GI blockage worse. That is because huperzine A can increase mucous and fluid secretions in the intestine, causing "congestion." If you have a GI tract blockage, check with your healthcare provider before you use huperzine A.
Sores in the stomach or the first part of the small intestine (peptic ulcers): There is a concern that using huperzine A might make peptic ulcers worse. That is because huperzine A can increase mucous and fluid secretions in the stomach and intestine, causing "congestion." If you have peptic ulcers, check with your healthcare provider before you use huperzine A.
Lung conditions such as asthma or emphysema: There is a concern that using huperzine A might make asthma or emphysema worse. That is because huperzine A can increase mucous and fluid secretions in the lung, causing "congestion." If you have asthma or emphysema, check with your healthcare provider before you use huperzine A.
Urinary tract or reproductive system blockage: There is a concern that using huperzine A might make blockage of the urinary or reproductive system worse. That is because huperzine A can increase mucous and fluid secretions in these organs, causing "congestion." If you have a urinary tract or reproductive system blockage, check with your healthcare provider before you use huperzine A.
Be cautious with this combination
Drying medications (Anticholinergic drugs) interacts with HUPERZINE A
Huperzine A contains chemicals that can affect the brain and heart. Some of these drying medications called anticholinergic drugs can also affect the brain and heart. But huperzine A works differently than drying medications. Huperzine A might decrease the effects of drying medications.<br/><br/> Some of these drying medications include atropine, scopolamine, and some medications used for allergies (antihistamines), and for depression (antidepressants).
Medications for Alzheimer's disease (Acetylcholinesterase (AChE) inhibitors) interacts with HUPERZINE A
Huperzine A contains a chemical that affects the brain. Medications for Alzheimer's disease also affect the brain. Taking Huperzine A along with medications for Alzheimer's disease might increase effects and side effects of medications for Alzheimer's disease.
Various medications used for glaucoma, Alzheimer's disease, and other conditions (Cholinergic drugs) interacts with HUPERZINE A
Huperzine A contains a chemical that affects the body. This chemical is similar to some medications used for glaucoma, Alzheimer's disease and other conditions. Taking Huperzine A with these medications might increase the chance of side effects.<br/><br/> Some of these medications used for glaucoma, Alzheimer's disease, and other conditions include pilocarpine (Pilocar and others), donepezil (Aricept), tacrine (Cognex), and others.
The following doses have been studied in scientific research:
- For dementia: The most commonly used doses for people with Alzheimer's disease are 300-500 mcg daily. In people with other types of dementia, 100 mcg twice daily has been used.
- For memory: 100 mcg twice daily has been used.
- For dementia: 30-50 mcg injected into the muscle twice daily by a healthcare provider has been used.
- Aisen, P. A Multi-Center, Double-Blind, Placebo-Controlled Therapeutic Trial to Determine Whether Natural Huperzine A Improves Cognitive Function. Georgetown University Medical Center, Memory Disorders Program 2004;
- Chen M, Gao Z, Deng H, and et al. Huperzine A capsules vs tablets in treatment of Alzheimer disease: multicenter studies. Chinese Journal of New Drugs and Clinical Remedies 2000;19(1):10-12.
- Cheng YS, Lu CZ, Ying ZL, and et al. [128 cases of myasthenia gravis treated with huperzine A]. New Drugs Clin Remedies 1986;5(4):197-199.
- Cheng, D. H., Ren, H., and Tang, X. C. Huperzine A, a novel promising acetylcholinesterase inhibitor. Neuroreport 12-20-1996;8(1):97-101. View abstract.
- Chow, T. W. Review: insufficient evidence on Huperzine A for Alzheimer's. Evid Based Ment.Health 2008;11(4):112. View abstract.
- Chu, D. F., Fu, X. Q., Liu, W. H., Liu, K., and Li, Y. X. Pharmacokinetics and in vitro and in vivo correlation of huperzine A loaded poly(lactic-co-glycolic acid) microspheres in dogs. Int J Pharm 11-15-2006;325(1-2):116-123. View abstract.
- Du ZM, Li SL, and Yang CF. [A randomised study of huperzine: a therapy on senile amnestic syndrome]. Chinese Journal of Geriatrics 1996;15(3):180.
- Filliat, P., Foquin, A., and Lallement, G. Effects of chronic administration of huperzine A on memory in guinea pigs. Drug Chem Toxicol 2002;25(1):9-24. View abstract.
- Finkelstein, B. L., Benner, E. A., Hendrixson, M. C., Kranis, K. T., Rauh, J. J., Sethuraman, M. R., and McCann, S. F. Tricyclic cyanoguanidines: synthesis, site of action and insecticidal activity of a novel class of reversible acetylcholinesterase inhibitors. Bioorg.Med Chem 2002;10(3):599-613. View abstract.
- Gao, P., Xu, H., Ding, P., Gao, Q., Sun, J., and Chen, D. Controlled release of huperzine A from biodegradable microspheres: In vitro and in vivo studies. Int J Pharm 2-7-2007;330(1-2):1-5. View abstract.
- Gordon, R. K., Nigam, S. V., Weitz, J. A., Dave, J. R., Doctor, B. P., and Ved, H. S. The NMDA receptor ion channel: a site for binding of Huperzine A. J Appl Toxicol 2001;21 Suppl 1:S47-S51. View abstract.
- Hao, Z., Liu, M., Liu, Z., and Lv, D. Huperzine A for vascular dementia. Cochrane Database Syst.Rev 2009;(2):CD007365. View abstract.
- Huperzine A. Drugs R.D. 2004;5(1):44-45. View abstract.
- Kuang, M. Clinical evaluation of huperzine A in improving interlligent disorder in patients with Alzheimer's disease. Zhongguo Linchuang Kangfu 2004;8(7):1216.
- Lallement, G. [Pretreatment of organophosphate poisoning: potential interests of huperzine A]. Ann Pharm Fr. 2000;58(1):13-17. View abstract.
- Lallement, G., Baille, V., Baubichon, D., Carpentier, P., Collombet, J. M., Filliat, P., Foquin, A., Four, E., Masqueliez, C., Testylier, G., Tonduli, L., and Dorandeu, F. Review of the value of huperzine as pretreatment of organophosphate poisoning. Neurotoxicology 2002;23(1):1-5. View abstract.
- Li, J., Wu, H. M., Zhou, R. L., Liu, G. J., and Dong, B. R. Huperzine A for Alzheimer's disease. Cochrane Database Syst.Rev 2008;(2):CD005592. View abstract.
- Li, K. Change of thyroid function in patients with Alzheimer disease after treatment of huperzine A. Zhongguo Linchuang Kangfu 2006;10(22):70.
- Li, Y. X., Zhang, R. Q., Li, C. R., and Jiang, X. H. Pharmacokinetics of huperzine A following oral administration to human volunteers. Eur J Drug Metab Pharmacokinet. 2007;32(4):183-187. View abstract.
- Little, J. T., Walsh, S., and Aisen, P. S. An update on huperzine A as a treatment for Alzheimer's disease. Expert.Opin.Investig.Drugs 2008;17(2):209-215. View abstract.
- Liu FG, Fang YS, Gao ZX, and et al. [Double-blind randomised controlled trial of huperzine-A in 28 patients with Alzheimer disease]. Journal of Pharmacoepidemiology 1995;4(4):196-198.
- Liu, W. H., Song, J. L., Liu, K., Chu, D. F., and Li, Y. X. Preparation and in vitro and in vivo release studies of Huperzine A loaded microspheres for the treatment of Alzheimer's disease. J Control Release 10-20-2005;107(3):417-427. View abstract.
- Ma, X. C., Xin, J., Wang, H. X., Zhang, T., and Tu, Z. H. Acute effects of huperzine A and tacrine on rat liver. Acta Pharmacol Sin. 2003;24(3):247-250. View abstract.
- Mazurek A. An open label trial of huperzine A in the treatment of Alzheimer's disease. Altern Ther 1999;5(2):97-98.
- Qian, B. C., Wang, M., Zhou, Z. F., Chen, K., Zhou, R. R., and Chen, G. S. Pharmacokinetics of tablet huperzine A in six volunteers. Zhongguo Yao Li Xue.Bao. 1995;16(5):396-398. View abstract.
- Ricordel, I. and Meunier, J. [Chemical weapons: antidotes. View about the real means, perspectives]. Ann Pharm Fr. 2000;58(1):5-12. View abstract.
- Tang XC and Han YF. Pharmacological profile of huperzine A, a novel acetylcholinesterase inhibitor from Chinese herb. Cns Drug Reviews 1999;5(3):281-300.
- Tang, L. L., Wang, R., and Tang, X. C. Huperzine A protects SHSY5Y neuroblastoma cells against oxidative stress damage via nerve growth factor production. Eur J Pharmacol 9-5-2005;519(1-2):9-15. View abstract.
- Tang, X. C. Huperzine A (shuangyiping): a promising drug for Alzheimer's disease. Zhongguo Yao Li Xue.Bao.(Acta Pharmacologica Sinica) 1996;17(6):481-484. View abstract.
- Tao, T., Zhao, Y., Yue, P., Dong, W. X., and Chen, Q. H. [Preparation of huperzine A nasal in situ gel and evaluation of its brain targeting following intranasal administration]. Yao Xue Xue Bao 2006;41(11):1104-1110. View abstract.
- Tonduli, L. S., Testylier, G., Masqueliez, C., Lallement, G., and Monmaur, P. Effects of Huperzine used as pre-treatment against soman-induced seizures. Neurotoxicology 2001;22(1):29-37. View abstract.
- Wang, G., Zhang, S. Q., and Zhan, H. [Effect of huperzine A on cerebral cholinesterase and acetylcholine in elderly patients during recovery from general anesthesia]. Nan Fang Yi Ke Da Xue Xue Bao 2006;26(11):1660-1662. View abstract.
- Wang, L. M., Han, Y. F., and Tang, X. C. Huperzine A improves cognitive deficits caused by chronic cerebral hypoperfusion in rats. Eur J Pharmacol 6-9-2000;398(1):65-72. View abstract.
- Wang, L. S., Zhou, J., Shao, X. M., and Tang, X. C. [Huperzine A attenuates cognitive deficits and brain injury after hypoxia-ischemic brain damage in neonatal rats]. Zhonghua Er.Ke Za Zhi 2003;41(1):42-45. View abstract.
- Wang, R., Xiao, X. Q., and Tang, X. C. Huperzine A attenuates hydrogen peroxide-induced apoptosis by regulating expression of apoptosis-related genes in rat PC12 cells. Neuroreport 8-28-2001;12(12):2629-2634. View abstract.
- Wang, W. Effect of huperzine A on memory function of patients with mild cognitive impairment. Zhongguo Linchuang Kangfu 2005;9(8):23.
- Wang, Z, Ren, G, Zhao, Y, and et al. A double-blind study of huperzine A and piracetam in patients with age-associated memory impairment and dementia. Herbal Medicines for Neuropsychiatric Diseases 1999;39-50.
- Xiao, X. Q., Wang, R., Han, Y. F., and Tang, X. C. Protective effects of huperzine A on beta-amyloid(25-35) induced oxidative injury in rat pheochromocytoma cells. Neurosci.Lett 6-9-2000;286(3):155-158. View abstract.
- Xiao, X. Q., Yang, J. W., and Tang, X. C. Huperzine A protects rat pheochromocytoma cells against hydrogen peroxide-induced injury. Neurosci.Lett 11-12-1999;275(2):73-76. View abstract.
- Xiao, X. Q., Zhang, H. Y., and Tang, X. C. Huperzine A attenuates amyloid beta-peptide fragment 25-35-induced apoptosis in rat cortical neurons via inhibiting reactive oxygen species formation and caspase-3 activation. J Neurosci.Res 1-1-2002;67(1):30-36. View abstract.
- Xiong, Z. Q. and Tang, X. C. Effect of huperzine A, a novel acetylcholinesterase inhibitor, on radial maze performance in rats. Pharmacol Biochem Behav 1995;51(2-3):415-419. View abstract.
- Xu SS, Gao ZX, Weng Z, and et al. Efficacy of tablet huperzine-A on memory, cognition and behavior in Alzheimer's disease. Int Med J 1997;4(2):127-131.
- Xue, SW., Ding, JM., Zhong, P., Liang, K., An, HY., and Bo, Y. Impacts of huperzine A on the level of Fas, Apo2.7 and Bcl-2 on the platelet membrane and the cognitive function in patients with Alzheimer disease. Zhongguo Linchuang Kangfu 2005;9(9):188.
- Yang, C. Efficacy and reliability of huperzine a in mild and moderate alzheimer's disease. Zhongguo Linchuang Kangfu 2003;7(31):4258.
- Ye, J. C., Zeng, S., Zheng, G. L., and Chen, G. S. Pharmacokinetics of Huperzine A after transdermal and oral administration in beagle dogs. Int J Pharm 5-22-2008;356(1-2):187-192. View abstract.
- Ye, J. W., Shang, Y. Z., Wang, Z. M., and Tang, X. C. Huperzine A ameliorates the impaired memory of aged rat in the Morris water maze performance. Acta Pharmacol Sin. 2000;21(1):65-69. View abstract.
- Yue, P., Tao, T., Zhao, Y., Ren, J., and Chai, X. Huperzine A in rat plasma and CSF following intranasal administration. Int J Pharm 6-7-2007;337(1-2):127-132. View abstract.
- Zhang, H. Y. and Tang, X. C. Huperzine A attenuates the neurotoxic effect of staurosporine in primary rat cortical neurons. Neurosci.Lett 4-10-2003;340(2):91-94. View abstract.
- Zhang, M. Evaluation of clinical effect and safety of huperzine A in treating 52 Alzheimer's disease. Journal of New Drugs and Clinical Remedies 2006;25:693.
- Zhang, Z. J., Tong, Y., Wang, X. Y., Yao, S. M., Jin, G. X., and Wang, X. P. Huperzine A as add-on therapy in patients with treatment-resistant schizophrenia: an open-labeled trial. Schizophr.Res 2007;92(1-3):273-275. View abstract.
- Zhang, Z., Wang, X., Chen, Q., Shu, L., Wang, J., and Shan, G. [Clinical efficacy and safety of huperzine Alpha in treatment of mild to moderate Alzheimer disease, a placebo-controlled, double-blind, randomized trial]. Zhonghua Yi Xue Za Zhi 7-25-2002;82(14):941-944. View abstract.
- Zhou, J. and Tang, X. C. Huperzine A attenuates apoptosis and mitochondria-dependent caspase-3 in rat cortical neurons. FEBS Lett 8-28-2002;526(1-3):21-25. View abstract.
- Zhou, J., Zhang, H. Y., and Tang, X. C. Huperzine A attenuates cognitive deficits and hippocampal neuronal damage after transient global ischemia in gerbils. Neurosci.Lett 11-9-2001;313(3):137-140. View abstract.
- Camps P, Cusack B, Mallender WD, et al. Huprine X is a novel high-affinity inhibitor of acetylcholinesterase that is of interest for treatment of Alzheimer's disease. Mol Pharmacol 2000;57:409-17. View abstract.
- Cheng DH, Tang XC. Comparative studies of huperzine A, E2020, and tacrine on behavior and cholinesterase activities. Pharmacol Biochem Behav 1998;60:377-86. View abstract.
- Cheng YS, Lu CZ, Ying ZL, et al. [128 cases of myasthenia gravis treated with huperzine A]. New Drugs and Clinical Remedies 1986;5:197-9.
- De La Garza R 2nd, Verrico CD, Newton TF, Mahoney JJ 3rd, Thompson-Lake DG. Safety and preliminary efficacy of the acetylcholinesterase inhibitor Huperzine A as a treatment for cocaine use disorder. Int J Neuropsychopharmacol 2015;19(3):pyv098. View abstract.
- Felgenhauer N, Zilker T, Worek F, Eyer P. Intoxication with huperzine A, a potent anticholinesterase found in the fir club moss. J Toxicol Clin Toxicol 2000;38:803-8.. View abstract.
- Grunwald J, Raveh L, Doctor BP, Ashani Y. Huperzine A as a pretreatment candidate drug against nerve agent toxicity. Life Sci 1994;54:991-7. View abstract.
- Jia JY, Zhao QH, Liu Y, et al. Phase I study on the pharmacokinetics and tolerance of ZT-1, a prodrug of huperzine A, for the treatment of Alzheimer's disease. Acta Pharmacol Sin 2013;34(7):976-82. View abstract.
- Lallement G, Veyret J, Masqueliez C, et al. Efficacy of huperzine in preventing soman-induced seizures, neuropathological changes and lethality. Fundam Clin Pharmacol 1997;11:387-94. View abstract.
- Li YX, Zhang RQ, Li CR, Jiang XH. Pharmacokinetics of huperzine A following oral administration to human volunteers. Eur J Drug Metab Pharmacokinet 2007;32(4):183-7. View abstract.
- Pepping J. Huperzine A. Am J Health Syst Pharm 2000;57:530-4.
- Rafii MS, Walsh S, Little JT, et al.; Alzheimer's Disease Cooperative Study. A phase II trial of huperzine A in mild to moderate Alzheimer disease. Neurology 2011;76(16):1389-94. View abstract.
- Safety Briefs, ISMP Medication Safety Alert, vol.4, #4. Institute for Safe Medication Practices, Warminster, PA. February 24, 1999.
- Skolnick AA. Old Chinese herbal medicine used for fever yields possible new Alzheimer Disease therapy. JAMA 1997;277:776.
- Sun QQ, Xu SS, Pan JL, et al. Huperzine-A capsules enhance memory and learning performance in 34 pairs of matched adolescent students. Chung Kuo Yao Li Hsueh Pao 1999;20:601-3. View abstract.
- Tang XC, De Sarno P, Sugaya K, Giacobini E. Effect of huperzine A, a new cholinesterase inhibitor, on the central cholinergic system of the rat. J Neurosci Res 1989;24:276-85. View abstract.
- Wang BS, Wang H, Wei ZH, Song YY, Zhang L, Chen HZ. Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer's disease: an updated meta-analysis. J Neural Transm (Vienna) 2009;116(4):457-65. View abstract.
- Wang H, Tang XC. Anticholinesterase effects of huperzine A, E2020, and tacrine in rats. Chung Kuo Yao Li Hsueh Pao 1998;19:27-30. View abstract.
- Wang T, Tang XC. Reversal of scopolamine-induced deficits in radial maze performance by (-)-huperzine A: comparison with E2020 and tacrine. Eur J Pharmacol 1998;349:137-42. View abstract.
- Wang XD, Zhang JM, Yang HH, Hu GY. Modulation of NMDA receptor by huperzine A in rat cerebral cortex. Chung Kuo Yao Li Hsueh Pao 1999;20:31-5. View abstract.
- Xing SH, Zhu CX, Zhang R, An L. Huperzine a in the treatment of Alzheimer's disease and vascular dementia: a meta-analysis. Evid Based Complement Alternat Med 2014;2014:363985. View abstract.
- Xiong ZQ, Cheng DH, Tang XC. Effects of huperzine A on nucleus basalis magnocellularis lesion-induced spatial working memory deficit. Chung Kuo Yao Li Hsueh Pao 1998;19:128-32. View abstract.
- Xu SS, Cai ZY, Qu ZW, et al. Huperzine-A in capsules and tablets for treating patients with Alzheimer disease. Zhongguo Yao Li Xue Bao 1999;20:486-90. View abstract.
- Xu SS, Gao ZX, Weng Z, et al. Efficacy of tablet huperzine-A on memory, cognition, and behavior in Alzheimer's disease. Zhongguo Yao Li Xue Bao 1995;16:391-5. View abstract.
- Xu ZQ, Liang XM, Juan-Wu, Zhang YF, Zhu CX, Jiang XJ. Treatment with Huperzine A improves cognition in vascular dementia patients. Cell Biochem Biophys 2012;62(1):55-8. View abstract.
- Yang G, Wang Y, Tian J, Liu JP. Huperzine A for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials. PLoS One 2013;8(9):e74916. View abstract.
- Ye JW, Cai JX, Wang LM, Tang XC. Improving effects of huperzine A on spatial working memory in aged monkeys and young adult monkeys with experimental cognitive impairment. J Pharmacol Exp Ther 1999;288:814-9.. View abstract.
- Zhang RW, Tang XC, Han YY, et al. [Drug evaluation of huperzine A in the treatment of senile memory disorders]. Chung Kuo Yao Li Hsueh Pao 1991;12:250-2. View abstract.
- Zhang SL. [Therapeutic effects of huperzine A on the aged with memory impairment]. New Drugs and Clinical Remedies 1986;5:260-2.
- Zheng W, Xiang YQ, Li XB, et al. Adjunctive huperzine A for cognitive deficits in schizophrenia: a systematic review and meta-analysis. Hum Psychopharmacol 2016;31(4):286-95. View abstract.
- Zheng W, Xiang YQ, Ungvari GS, et al. Huperzine A for treatment of cognitive impairment in major depressive disorder: a systematic review of randomized controlled trials. Shanghai Arch Psychiatry 2016;28(2):64-71. View abstract.
Have you ever purchased HUPERZINE A?
Did you or will you purchase this product in-store or online?
Where did you or where do you plan to purchase this product?
Where did you or where do you plan to purchase this product?
What factors influenced or will influence your purchase? (check all that apply)
Where did you or where do you plan to purchase this product?
Do you buy vitamins online or instore?
What factors are most important to you? (check all that apply)